Form 4: Astria Therapeutics CCO Sells Shares Post-Merger

Astria Therapeutics' Chief Commercial Officer, Andrew Komjathy, reported the disposition of all his beneficial holdings in Astria common stock and stock options following the company's merger with BioCryst Pharmaceuticals.

Summary

• Andrew Komjathy, Chief Commercial Officer of Astria Therapeutics, Inc. (ATXS), reported the disposition of all his beneficial ownership in the company's common stock and stock options.
• The transactions occurred on January 23, 2026, following the merger of Astria Therapeutics with Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc. (BioCryst).
• At the effective time of the merger, Astria Therapeutics became a wholly-owned subsidiary of BioCryst.
• Each outstanding share of Astria common stock was converted into the right to receive 0.59 shares of BioCryst common stock and $8.55 in cash, subject to withholding taxes.
• In-the-money stock options (exercise price less than $13.00) became fully vested and were canceled in exchange for a cash payment equal to the product of the number of shares and the excess of $13.00 over the exercise price.
• Out-of-the-money stock options (exercise price equal to or greater than $13.00) were canceled for no consideration.
• Mr. Komjathy disposed of 10 shares of common stock directly, 45 shares indirectly held in a Uniform Transfers to Minors Act (UTMA) account, and 45 shares indirectly held by his adult child.
• He also disposed of 55,000 stock options with an exercise price of $6.51 and 225,000 stock options with an exercise price of $6.41.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive for the reporting person, as their in-the-money equity holdings were successfully monetized as part of a corporate merger. The cancellation of out-of-the-money options is a standard outcome in such scenarios and does not detract significantly from the overall positive resolution of their equity position.

Positives

• The merger successfully completed, resulting in Astria Therapeutics becoming a wholly-owned subsidiary of BioCryst Pharmaceuticals.
• In-the-money stock options held by the reporting person were monetized for a cash payment, providing liquidity.
• Shareholders of Astria Therapeutics received a combination of BioCryst common stock and cash for their shares.

Negatives

• Out-of-the-money stock options held by the reporting person were canceled for no consideration, resulting in a loss of potential value for those specific options.

Risks

• The filing does not detail specific company-level risks, as it is an insider transaction report following a merger. However, the cancellation of out-of-the-money options for no consideration highlights the risk associated with equity compensation tied to specific price thresholds.

Future Outlook

This Form 4 filing reports a completed transaction and does not contain forward-looking statements or guidance regarding the future operations or financial performance of the merged entity.

Industry Context

The merger of Astria Therapeutics into BioCryst Pharmaceuticals is consistent with ongoing consolidation trends within the biotechnology and pharmaceutical sectors, where larger companies acquire smaller, specialized firms to expand pipelines or market share. Such transactions often lead to the restructuring of equity holdings for executives of the acquired entity.

Comparison to Industry Standards

• The merger consideration, combining stock and cash, is a common structure in biotech M&A, offering both immediate liquidity and participation in the acquiring company's future performance.
• The treatment of stock options, with in-the-money options being cashed out and out-of-the-money options canceled, aligns with standard practices in corporate mergers and acquisitions to simplify equity structures post-transaction.

Related Party Transactions

• The reporting person disclaims beneficial ownership over 45 shares held in a Uniform Transfers to Minors Act (UTMA) brokerage account of their minor child, for which they serve as custodian trustee, except to the extent of their indirect pecuniary interest.
• The reporting person disclaims beneficial ownership over 45 shares held directly by their adult child.

Stakeholder Impact

• Shareholders of Astria Therapeutics received merger consideration in the form of BioCryst common stock and cash, realizing value for their investment.
• Employees, including the Chief Commercial Officer, had their equity compensation (stock and options) converted or cashed out as part of the merger terms.

Key Dates

Keywords

Astria Therapeutics, ATXS, BioCryst Pharmaceuticals, Merger, Form 4, Insider Transaction, Stock Options, Common Stock, Chief Commercial Officer, Equity Compensation